nodes	percent_of_prediction	percent_of_DWPC	metapath
Fentanyl—ABCB1—Mitomycin—urinary bladder cancer	0.164	0.338	CbGbCtD
Fentanyl—CYP3A4—Thiotepa—urinary bladder cancer	0.0746	0.154	CbGbCtD
Fentanyl—CYP3A5—Etoposide—urinary bladder cancer	0.0519	0.107	CbGbCtD
Fentanyl—ABCB1—Gemcitabine—urinary bladder cancer	0.0473	0.0974	CbGbCtD
Fentanyl—ABCB1—Cisplatin—urinary bladder cancer	0.0344	0.0708	CbGbCtD
Fentanyl—ABCB1—Etoposide—urinary bladder cancer	0.0338	0.0695	CbGbCtD
Fentanyl—ABCB1—Doxorubicin—urinary bladder cancer	0.023	0.0474	CbGbCtD
Fentanyl—ABCB1—Methotrexate—urinary bladder cancer	0.0223	0.0459	CbGbCtD
Fentanyl—CYP3A4—Etoposide—urinary bladder cancer	0.0202	0.0417	CbGbCtD
Fentanyl—CYP3A4—Doxorubicin—urinary bladder cancer	0.0138	0.0284	CbGbCtD
Fentanyl—Benzphetamine—POR—urinary bladder cancer	0.00191	0.519	CrCbGaD
Fentanyl—Benazepril—MTHFR—urinary bladder cancer	0.00139	0.378	CrCbGaD
Fentanyl—Phenylbutazone—PTGS2—urinary bladder cancer	0.000377	0.103	CrCbGaD
Fentanyl—Immune system disorder—Methotrexate—urinary bladder cancer	0.000155	0.000318	CcSEcCtD
Fentanyl—Dizziness—Fluorouracil—urinary bladder cancer	0.000155	0.000318	CcSEcCtD
Fentanyl—Visual impairment—Epirubicin—urinary bladder cancer	0.000155	0.000318	CcSEcCtD
Fentanyl—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000155	0.000318	CcSEcCtD
Fentanyl—Chills—Methotrexate—urinary bladder cancer	0.000154	0.000316	CcSEcCtD
Fentanyl—Diarrhoea—Cisplatin—urinary bladder cancer	0.000152	0.000312	CcSEcCtD
Fentanyl—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000152	0.000312	CcSEcCtD
Fentanyl—Alopecia—Methotrexate—urinary bladder cancer	0.000152	0.000311	CcSEcCtD
Fentanyl—Vomiting—Gemcitabine—urinary bladder cancer	0.000152	0.000311	CcSEcCtD
Fentanyl—Bradycardia—Doxorubicin—urinary bladder cancer	0.000152	0.000311	CcSEcCtD
Fentanyl—Mental disorder—Methotrexate—urinary bladder cancer	0.000151	0.000309	CcSEcCtD
Fentanyl—Rash—Gemcitabine—urinary bladder cancer	0.000151	0.000309	CcSEcCtD
Fentanyl—Dermatitis—Gemcitabine—urinary bladder cancer	0.00015	0.000308	CcSEcCtD
Fentanyl—Eye disorder—Epirubicin—urinary bladder cancer	0.00015	0.000308	CcSEcCtD
Fentanyl—Hypersensitivity—Etoposide—urinary bladder cancer	0.00015	0.000308	CcSEcCtD
Fentanyl—Tinnitus—Epirubicin—urinary bladder cancer	0.00015	0.000307	CcSEcCtD
Fentanyl—Malnutrition—Methotrexate—urinary bladder cancer	0.00015	0.000307	CcSEcCtD
Fentanyl—Erythema—Methotrexate—urinary bladder cancer	0.00015	0.000307	CcSEcCtD
Fentanyl—Haemoglobin—Doxorubicin—urinary bladder cancer	0.00015	0.000307	CcSEcCtD
Fentanyl—Headache—Gemcitabine—urinary bladder cancer	0.00015	0.000307	CcSEcCtD
Fentanyl—Flushing—Epirubicin—urinary bladder cancer	0.000149	0.000306	CcSEcCtD
Fentanyl—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000149	0.000306	CcSEcCtD
Fentanyl—Vomiting—Fluorouracil—urinary bladder cancer	0.000149	0.000306	CcSEcCtD
Fentanyl—Rhinitis—Doxorubicin—urinary bladder cancer	0.000149	0.000306	CcSEcCtD
Fentanyl—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000149	0.000305	CcSEcCtD
Fentanyl—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000148	0.000304	CcSEcCtD
Fentanyl—Rash—Fluorouracil—urinary bladder cancer	0.000148	0.000303	CcSEcCtD
Fentanyl—Dermatitis—Fluorouracil—urinary bladder cancer	0.000148	0.000303	CcSEcCtD
Fentanyl—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000148	0.000303	CcSEcCtD
Fentanyl—Headache—Fluorouracil—urinary bladder cancer	0.000147	0.000301	CcSEcCtD
Fentanyl—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000147	0.000301	CcSEcCtD
Fentanyl—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000147	0.000301	CcSEcCtD
Fentanyl—Dysgeusia—Methotrexate—urinary bladder cancer	0.000147	0.0003	CcSEcCtD
Fentanyl—Asthenia—Etoposide—urinary bladder cancer	0.000146	0.0003	CcSEcCtD
Fentanyl—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000146	0.0003	CcSEcCtD
Fentanyl—Angiopathy—Epirubicin—urinary bladder cancer	0.000146	0.000299	CcSEcCtD
Fentanyl—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000146	0.000299	CcSEcCtD
Fentanyl—Immune system disorder—Epirubicin—urinary bladder cancer	0.000145	0.000298	CcSEcCtD
Fentanyl—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000145	0.000297	CcSEcCtD
Fentanyl—Back pain—Methotrexate—urinary bladder cancer	0.000145	0.000297	CcSEcCtD
Fentanyl—Chills—Epirubicin—urinary bladder cancer	0.000144	0.000296	CcSEcCtD
Fentanyl—Pruritus—Etoposide—urinary bladder cancer	0.000144	0.000296	CcSEcCtD
Fentanyl—Arrhythmia—Epirubicin—urinary bladder cancer	0.000144	0.000295	CcSEcCtD
Fentanyl—Visual impairment—Doxorubicin—urinary bladder cancer	0.000143	0.000294	CcSEcCtD
Fentanyl—Alopecia—Epirubicin—urinary bladder cancer	0.000142	0.000291	CcSEcCtD
Fentanyl—Nausea—Gemcitabine—urinary bladder cancer	0.000142	0.000291	CcSEcCtD
Fentanyl—Vomiting—Cisplatin—urinary bladder cancer	0.000142	0.00029	CcSEcCtD
Fentanyl—Vision blurred—Methotrexate—urinary bladder cancer	0.000141	0.000289	CcSEcCtD
Fentanyl—Mental disorder—Epirubicin—urinary bladder cancer	0.000141	0.000289	CcSEcCtD
Fentanyl—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000141	0.000288	CcSEcCtD
Fentanyl—Rash—Cisplatin—urinary bladder cancer	0.00014	0.000288	CcSEcCtD
Fentanyl—Dermatitis—Cisplatin—urinary bladder cancer	0.00014	0.000287	CcSEcCtD
Fentanyl—Erythema—Epirubicin—urinary bladder cancer	0.00014	0.000287	CcSEcCtD
Fentanyl—Malnutrition—Epirubicin—urinary bladder cancer	0.00014	0.000287	CcSEcCtD
Fentanyl—Diarrhoea—Etoposide—urinary bladder cancer	0.00014	0.000286	CcSEcCtD
Fentanyl—Nausea—Fluorouracil—urinary bladder cancer	0.000139	0.000286	CcSEcCtD
Fentanyl—Eye disorder—Doxorubicin—urinary bladder cancer	0.000139	0.000285	CcSEcCtD
Fentanyl—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000139	0.000285	CcSEcCtD
Fentanyl—Tinnitus—Doxorubicin—urinary bladder cancer	0.000139	0.000284	CcSEcCtD
Fentanyl—Anaemia—Methotrexate—urinary bladder cancer	0.000138	0.000284	CcSEcCtD
Fentanyl—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000138	0.000283	CcSEcCtD
Fentanyl—Flushing—Doxorubicin—urinary bladder cancer	0.000138	0.000283	CcSEcCtD
Fentanyl—Flatulence—Epirubicin—urinary bladder cancer	0.000138	0.000283	CcSEcCtD
Fentanyl—Tension—Epirubicin—urinary bladder cancer	0.000137	0.000282	CcSEcCtD
Fentanyl—Dysgeusia—Epirubicin—urinary bladder cancer	0.000137	0.000281	CcSEcCtD
Fentanyl—Nervousness—Epirubicin—urinary bladder cancer	0.000136	0.000279	CcSEcCtD
Fentanyl—Back pain—Epirubicin—urinary bladder cancer	0.000135	0.000278	CcSEcCtD
Fentanyl—Angiopathy—Doxorubicin—urinary bladder cancer	0.000135	0.000277	CcSEcCtD
Fentanyl—Malaise—Methotrexate—urinary bladder cancer	0.000135	0.000277	CcSEcCtD
Fentanyl—Dizziness—Etoposide—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Fentanyl—Muscle spasms—Epirubicin—urinary bladder cancer	0.000135	0.000276	CcSEcCtD
Fentanyl—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000134	0.000276	CcSEcCtD
Fentanyl—Vertigo—Methotrexate—urinary bladder cancer	0.000134	0.000276	CcSEcCtD
Fentanyl—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000134	0.000275	CcSEcCtD
Fentanyl—Leukopenia—Methotrexate—urinary bladder cancer	0.000134	0.000275	CcSEcCtD
Fentanyl—Chills—Doxorubicin—urinary bladder cancer	0.000134	0.000274	CcSEcCtD
Fentanyl—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000133	0.000273	CcSEcCtD
Fentanyl—Nausea—Cisplatin—urinary bladder cancer	0.000132	0.000271	CcSEcCtD
Fentanyl—Vision blurred—Epirubicin—urinary bladder cancer	0.000132	0.000271	CcSEcCtD
Fentanyl—Alopecia—Doxorubicin—urinary bladder cancer	0.000132	0.00027	CcSEcCtD
Fentanyl—Cough—Methotrexate—urinary bladder cancer	0.000131	0.000268	CcSEcCtD
Fentanyl—Mental disorder—Doxorubicin—urinary bladder cancer	0.00013	0.000267	CcSEcCtD
Fentanyl—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Fentanyl—Convulsion—Methotrexate—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Fentanyl—Vomiting—Etoposide—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Fentanyl—Malnutrition—Doxorubicin—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Fentanyl—Erythema—Doxorubicin—urinary bladder cancer	0.00013	0.000266	CcSEcCtD
Fentanyl—Anaemia—Epirubicin—urinary bladder cancer	0.000129	0.000265	CcSEcCtD
Fentanyl—Agitation—Epirubicin—urinary bladder cancer	0.000129	0.000264	CcSEcCtD
Fentanyl—Rash—Etoposide—urinary bladder cancer	0.000129	0.000264	CcSEcCtD
Fentanyl—Dermatitis—Etoposide—urinary bladder cancer	0.000128	0.000263	CcSEcCtD
Fentanyl—Headache—Etoposide—urinary bladder cancer	0.000128	0.000262	CcSEcCtD
Fentanyl—Flatulence—Doxorubicin—urinary bladder cancer	0.000128	0.000262	CcSEcCtD
Fentanyl—Arthralgia—Methotrexate—urinary bladder cancer	0.000127	0.000261	CcSEcCtD
Fentanyl—Chest pain—Methotrexate—urinary bladder cancer	0.000127	0.000261	CcSEcCtD
Fentanyl—Myalgia—Methotrexate—urinary bladder cancer	0.000127	0.000261	CcSEcCtD
Fentanyl—Tension—Doxorubicin—urinary bladder cancer	0.000127	0.000261	CcSEcCtD
Fentanyl—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000127	0.00026	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000127	0.000259	CcSEcCtD
Fentanyl—Malaise—Epirubicin—urinary bladder cancer	0.000126	0.000259	CcSEcCtD
Fentanyl—Discomfort—Methotrexate—urinary bladder cancer	0.000126	0.000258	CcSEcCtD
Fentanyl—Nervousness—Doxorubicin—urinary bladder cancer	0.000126	0.000258	CcSEcCtD
Fentanyl—Vertigo—Epirubicin—urinary bladder cancer	0.000126	0.000258	CcSEcCtD
Fentanyl—Syncope—Epirubicin—urinary bladder cancer	0.000126	0.000257	CcSEcCtD
Fentanyl—Leukopenia—Epirubicin—urinary bladder cancer	0.000125	0.000257	CcSEcCtD
Fentanyl—Back pain—Doxorubicin—urinary bladder cancer	0.000125	0.000257	CcSEcCtD
Fentanyl—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000125	0.000255	CcSEcCtD
Fentanyl—Palpitations—Epirubicin—urinary bladder cancer	0.000124	0.000254	CcSEcCtD
Fentanyl—Confusional state—Methotrexate—urinary bladder cancer	0.000123	0.000252	CcSEcCtD
Fentanyl—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000123	0.000252	CcSEcCtD
Fentanyl—Cough—Epirubicin—urinary bladder cancer	0.000122	0.00025	CcSEcCtD
Fentanyl—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000122	0.00025	CcSEcCtD
Fentanyl—Vision blurred—Doxorubicin—urinary bladder cancer	0.000122	0.00025	CcSEcCtD
Fentanyl—Convulsion—Epirubicin—urinary bladder cancer	0.000121	0.000249	CcSEcCtD
Fentanyl—Infection—Methotrexate—urinary bladder cancer	0.000121	0.000249	CcSEcCtD
Fentanyl—Nausea—Etoposide—urinary bladder cancer	0.000121	0.000248	CcSEcCtD
Fentanyl—Hypertension—Epirubicin—urinary bladder cancer	0.000121	0.000248	CcSEcCtD
Fentanyl—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00012	0.000246	CcSEcCtD
Fentanyl—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00012	0.000246	CcSEcCtD
Fentanyl—Anaemia—Doxorubicin—urinary bladder cancer	0.00012	0.000245	CcSEcCtD
Fentanyl—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00012	0.000245	CcSEcCtD
Fentanyl—Arthralgia—Epirubicin—urinary bladder cancer	0.000119	0.000244	CcSEcCtD
Fentanyl—Chest pain—Epirubicin—urinary bladder cancer	0.000119	0.000244	CcSEcCtD
Fentanyl—Myalgia—Epirubicin—urinary bladder cancer	0.000119	0.000244	CcSEcCtD
Fentanyl—Agitation—Doxorubicin—urinary bladder cancer	0.000119	0.000244	CcSEcCtD
Fentanyl—Anxiety—Epirubicin—urinary bladder cancer	0.000119	0.000244	CcSEcCtD
Fentanyl—Skin disorder—Methotrexate—urinary bladder cancer	0.000119	0.000243	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000118	0.000243	CcSEcCtD
Fentanyl—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000118	0.000242	CcSEcCtD
Fentanyl—Discomfort—Epirubicin—urinary bladder cancer	0.000118	0.000241	CcSEcCtD
Fentanyl—Malaise—Doxorubicin—urinary bladder cancer	0.000117	0.00024	CcSEcCtD
Fentanyl—Dry mouth—Epirubicin—urinary bladder cancer	0.000117	0.000239	CcSEcCtD
Fentanyl—Vertigo—Doxorubicin—urinary bladder cancer	0.000116	0.000239	CcSEcCtD
Fentanyl—Anorexia—Methotrexate—urinary bladder cancer	0.000116	0.000239	CcSEcCtD
Fentanyl—Syncope—Doxorubicin—urinary bladder cancer	0.000116	0.000238	CcSEcCtD
Fentanyl—Leukopenia—Doxorubicin—urinary bladder cancer	0.000116	0.000238	CcSEcCtD
Fentanyl—Confusional state—Epirubicin—urinary bladder cancer	0.000115	0.000236	CcSEcCtD
Fentanyl—Palpitations—Doxorubicin—urinary bladder cancer	0.000115	0.000235	CcSEcCtD
Fentanyl—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000114	0.000234	CcSEcCtD
Fentanyl—Oedema—Epirubicin—urinary bladder cancer	0.000114	0.000234	CcSEcCtD
Fentanyl—Hypotension—Methotrexate—urinary bladder cancer	0.000114	0.000234	CcSEcCtD
Fentanyl—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000114	0.000233	CcSEcCtD
Fentanyl—Infection—Epirubicin—urinary bladder cancer	0.000114	0.000233	CcSEcCtD
Fentanyl—Cough—Doxorubicin—urinary bladder cancer	0.000113	0.000232	CcSEcCtD
Fentanyl—Shock—Epirubicin—urinary bladder cancer	0.000112	0.00023	CcSEcCtD
Fentanyl—Convulsion—Doxorubicin—urinary bladder cancer	0.000112	0.00023	CcSEcCtD
Fentanyl—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000112	0.00023	CcSEcCtD
Fentanyl—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000112	0.000229	CcSEcCtD
Fentanyl—Hypertension—Doxorubicin—urinary bladder cancer	0.000112	0.000229	CcSEcCtD
Fentanyl—Tachycardia—Epirubicin—urinary bladder cancer	0.000112	0.000229	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000111	0.000228	CcSEcCtD
Fentanyl—Skin disorder—Epirubicin—urinary bladder cancer	0.000111	0.000228	CcSEcCtD
Fentanyl—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00011	0.000226	CcSEcCtD
Fentanyl—Insomnia—Methotrexate—urinary bladder cancer	0.00011	0.000226	CcSEcCtD
Fentanyl—Arthralgia—Doxorubicin—urinary bladder cancer	0.00011	0.000226	CcSEcCtD
Fentanyl—Myalgia—Doxorubicin—urinary bladder cancer	0.00011	0.000226	CcSEcCtD
Fentanyl—Chest pain—Doxorubicin—urinary bladder cancer	0.00011	0.000226	CcSEcCtD
Fentanyl—Anxiety—Doxorubicin—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Fentanyl—Paraesthesia—Methotrexate—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Fentanyl—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00011	0.000225	CcSEcCtD
Fentanyl—Discomfort—Doxorubicin—urinary bladder cancer	0.000109	0.000223	CcSEcCtD
Fentanyl—Anorexia—Epirubicin—urinary bladder cancer	0.000109	0.000223	CcSEcCtD
Fentanyl—Dyspnoea—Methotrexate—urinary bladder cancer	0.000109	0.000223	CcSEcCtD
Fentanyl—Somnolence—Methotrexate—urinary bladder cancer	0.000109	0.000223	CcSEcCtD
Fentanyl—Dry mouth—Doxorubicin—urinary bladder cancer	0.000108	0.000221	CcSEcCtD
Fentanyl—Dyspepsia—Methotrexate—urinary bladder cancer	0.000108	0.00022	CcSEcCtD
Fentanyl—Hypotension—Epirubicin—urinary bladder cancer	0.000107	0.000219	CcSEcCtD
Fentanyl—Confusional state—Doxorubicin—urinary bladder cancer	0.000107	0.000219	CcSEcCtD
Fentanyl—Decreased appetite—Methotrexate—urinary bladder cancer	0.000106	0.000218	CcSEcCtD
Fentanyl—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000106	0.000217	CcSEcCtD
Fentanyl—Oedema—Doxorubicin—urinary bladder cancer	0.000106	0.000217	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000105	0.000216	CcSEcCtD
Fentanyl—Fatigue—Methotrexate—urinary bladder cancer	0.000105	0.000216	CcSEcCtD
Fentanyl—Infection—Doxorubicin—urinary bladder cancer	0.000105	0.000215	CcSEcCtD
Fentanyl—Pain—Methotrexate—urinary bladder cancer	0.000104	0.000214	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000104	0.000213	CcSEcCtD
Fentanyl—Shock—Doxorubicin—urinary bladder cancer	0.000104	0.000213	CcSEcCtD
Fentanyl—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000104	0.000213	CcSEcCtD
Fentanyl—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000104	0.000212	CcSEcCtD
Fentanyl—Insomnia—Epirubicin—urinary bladder cancer	0.000103	0.000212	CcSEcCtD
Fentanyl—Tachycardia—Doxorubicin—urinary bladder cancer	0.000103	0.000212	CcSEcCtD
Fentanyl—Skin disorder—Doxorubicin—urinary bladder cancer	0.000103	0.000211	CcSEcCtD
Fentanyl—Paraesthesia—Epirubicin—urinary bladder cancer	0.000103	0.00021	CcSEcCtD
Fentanyl—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000102	0.00021	CcSEcCtD
Fentanyl—Dyspnoea—Epirubicin—urinary bladder cancer	0.000102	0.000209	CcSEcCtD
Fentanyl—Somnolence—Epirubicin—urinary bladder cancer	0.000102	0.000208	CcSEcCtD
Fentanyl—Anorexia—Doxorubicin—urinary bladder cancer	0.000101	0.000207	CcSEcCtD
Fentanyl—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000101	0.000206	CcSEcCtD
Fentanyl—Dyspepsia—Epirubicin—urinary bladder cancer	0.000101	0.000206	CcSEcCtD
Fentanyl—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.99e-05	0.000205	CcSEcCtD
Fentanyl—Decreased appetite—Epirubicin—urinary bladder cancer	9.94e-05	0.000204	CcSEcCtD
Fentanyl—Hypotension—Doxorubicin—urinary bladder cancer	9.88e-05	0.000203	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.87e-05	0.000202	CcSEcCtD
Fentanyl—Fatigue—Epirubicin—urinary bladder cancer	9.85e-05	0.000202	CcSEcCtD
Fentanyl—Pain—Epirubicin—urinary bladder cancer	9.77e-05	0.0002	CcSEcCtD
Fentanyl—Constipation—Epirubicin—urinary bladder cancer	9.77e-05	0.0002	CcSEcCtD
Fentanyl—Urticaria—Methotrexate—urinary bladder cancer	9.7e-05	0.000199	CcSEcCtD
Fentanyl—Abdominal pain—Methotrexate—urinary bladder cancer	9.66e-05	0.000198	CcSEcCtD
Fentanyl—Body temperature increased—Methotrexate—urinary bladder cancer	9.66e-05	0.000198	CcSEcCtD
Fentanyl—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	9.64e-05	0.000197	CcSEcCtD
Fentanyl—Insomnia—Doxorubicin—urinary bladder cancer	9.57e-05	0.000196	CcSEcCtD
Fentanyl—Paraesthesia—Doxorubicin—urinary bladder cancer	9.5e-05	0.000195	CcSEcCtD
Fentanyl—Dyspnoea—Doxorubicin—urinary bladder cancer	9.43e-05	0.000193	CcSEcCtD
Fentanyl—Feeling abnormal—Epirubicin—urinary bladder cancer	9.42e-05	0.000193	CcSEcCtD
Fentanyl—Somnolence—Doxorubicin—urinary bladder cancer	9.4e-05	0.000193	CcSEcCtD
Fentanyl—Gastrointestinal pain—Epirubicin—urinary bladder cancer	9.35e-05	0.000192	CcSEcCtD
Fentanyl—Dyspepsia—Doxorubicin—urinary bladder cancer	9.31e-05	0.000191	CcSEcCtD
Fentanyl—Decreased appetite—Doxorubicin—urinary bladder cancer	9.19e-05	0.000188	CcSEcCtD
Fentanyl—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	9.13e-05	0.000187	CcSEcCtD
Fentanyl—Fatigue—Doxorubicin—urinary bladder cancer	9.12e-05	0.000187	CcSEcCtD
Fentanyl—Urticaria—Epirubicin—urinary bladder cancer	9.08e-05	0.000186	CcSEcCtD
Fentanyl—Pain—Doxorubicin—urinary bladder cancer	9.04e-05	0.000185	CcSEcCtD
Fentanyl—Constipation—Doxorubicin—urinary bladder cancer	9.04e-05	0.000185	CcSEcCtD
Fentanyl—Abdominal pain—Epirubicin—urinary bladder cancer	9.04e-05	0.000185	CcSEcCtD
Fentanyl—Body temperature increased—Epirubicin—urinary bladder cancer	9.04e-05	0.000185	CcSEcCtD
Fentanyl—Hypersensitivity—Methotrexate—urinary bladder cancer	9e-05	0.000184	CcSEcCtD
Fentanyl—Asthenia—Methotrexate—urinary bladder cancer	8.76e-05	0.00018	CcSEcCtD
Fentanyl—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.72e-05	0.000179	CcSEcCtD
Fentanyl—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.65e-05	0.000177	CcSEcCtD
Fentanyl—Pruritus—Methotrexate—urinary bladder cancer	8.64e-05	0.000177	CcSEcCtD
Fentanyl—Hypersensitivity—Epirubicin—urinary bladder cancer	8.42e-05	0.000173	CcSEcCtD
Fentanyl—Urticaria—Doxorubicin—urinary bladder cancer	8.4e-05	0.000172	CcSEcCtD
Fentanyl—Abdominal pain—Doxorubicin—urinary bladder cancer	8.36e-05	0.000171	CcSEcCtD
Fentanyl—Body temperature increased—Doxorubicin—urinary bladder cancer	8.36e-05	0.000171	CcSEcCtD
Fentanyl—Diarrhoea—Methotrexate—urinary bladder cancer	8.36e-05	0.000171	CcSEcCtD
Fentanyl—Asthenia—Epirubicin—urinary bladder cancer	8.2e-05	0.000168	CcSEcCtD
Fentanyl—Pruritus—Epirubicin—urinary bladder cancer	8.09e-05	0.000166	CcSEcCtD
Fentanyl—Dizziness—Methotrexate—urinary bladder cancer	8.08e-05	0.000166	CcSEcCtD
Fentanyl—Diarrhoea—Epirubicin—urinary bladder cancer	7.82e-05	0.00016	CcSEcCtD
Fentanyl—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.79e-05	0.00016	CcSEcCtD
Fentanyl—Vomiting—Methotrexate—urinary bladder cancer	7.77e-05	0.000159	CcSEcCtD
Fentanyl—Rash—Methotrexate—urinary bladder cancer	7.7e-05	0.000158	CcSEcCtD
Fentanyl—Dermatitis—Methotrexate—urinary bladder cancer	7.69e-05	0.000158	CcSEcCtD
Fentanyl—Headache—Methotrexate—urinary bladder cancer	7.65e-05	0.000157	CcSEcCtD
Fentanyl—Asthenia—Doxorubicin—urinary bladder cancer	7.59e-05	0.000156	CcSEcCtD
Fentanyl—Dizziness—Epirubicin—urinary bladder cancer	7.56e-05	0.000155	CcSEcCtD
Fentanyl—Pruritus—Doxorubicin—urinary bladder cancer	7.48e-05	0.000153	CcSEcCtD
Fentanyl—Vomiting—Epirubicin—urinary bladder cancer	7.27e-05	0.000149	CcSEcCtD
Fentanyl—Nausea—Methotrexate—urinary bladder cancer	7.25e-05	0.000149	CcSEcCtD
Fentanyl—Diarrhoea—Doxorubicin—urinary bladder cancer	7.24e-05	0.000148	CcSEcCtD
Fentanyl—Rash—Epirubicin—urinary bladder cancer	7.21e-05	0.000148	CcSEcCtD
Fentanyl—Dermatitis—Epirubicin—urinary bladder cancer	7.2e-05	0.000148	CcSEcCtD
Fentanyl—Headache—Epirubicin—urinary bladder cancer	7.16e-05	0.000147	CcSEcCtD
Fentanyl—Dizziness—Doxorubicin—urinary bladder cancer	6.99e-05	0.000143	CcSEcCtD
Fentanyl—Nausea—Epirubicin—urinary bladder cancer	6.79e-05	0.000139	CcSEcCtD
Fentanyl—Vomiting—Doxorubicin—urinary bladder cancer	6.72e-05	0.000138	CcSEcCtD
Fentanyl—Rash—Doxorubicin—urinary bladder cancer	6.67e-05	0.000137	CcSEcCtD
Fentanyl—Dermatitis—Doxorubicin—urinary bladder cancer	6.66e-05	0.000137	CcSEcCtD
Fentanyl—Headache—Doxorubicin—urinary bladder cancer	6.63e-05	0.000136	CcSEcCtD
Fentanyl—Nausea—Doxorubicin—urinary bladder cancer	6.28e-05	0.000129	CcSEcCtD
Fentanyl—OPRK1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	4.21e-05	0.00183	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	4.15e-05	0.00181	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.99e-05	0.00174	CbGpPWpGaD
Fentanyl—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.95e-05	0.00172	CbGpPWpGaD
Fentanyl—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	3.91e-05	0.0017	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.82e-05	0.00166	CbGpPWpGaD
Fentanyl—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.82e-05	0.00166	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.81e-05	0.00166	CbGpPWpGaD
Fentanyl—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	3.79e-05	0.00165	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—HDAC4—urinary bladder cancer	3.77e-05	0.00164	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	3.74e-05	0.00163	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.71e-05	0.00162	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.64e-05	0.00159	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—GLI1—urinary bladder cancer	3.61e-05	0.00157	CbGpPWpGaD
Fentanyl—OPRM1—G alpha (i) signalling events—CXCL8—urinary bladder cancer	3.56e-05	0.00155	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	3.53e-05	0.00154	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	3.46e-05	0.00151	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	3.44e-05	0.0015	CbGpPWpGaD
Fentanyl—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.35e-05	0.00146	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	3.28e-05	0.00143	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—NAT1—urinary bladder cancer	3.28e-05	0.00143	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.23e-05	0.00141	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—HDAC4—urinary bladder cancer	3.19e-05	0.00139	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—GLI1—urinary bladder cancer	3.16e-05	0.00138	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.11e-05	0.00136	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	3e-05	0.00131	CbGpPWpGaD
Fentanyl—OPRD1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.91e-05	0.00127	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.85e-05	0.00124	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.84e-05	0.00124	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.83e-05	0.00123	CbGpPWpGaD
Fentanyl—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	2.83e-05	0.00123	CbGpPWpGaD
Fentanyl—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.78e-05	0.00121	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—TYMP—urinary bladder cancer	2.75e-05	0.0012	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	2.7e-05	0.00118	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—GLI1—urinary bladder cancer	2.67e-05	0.00116	CbGpPWpGaD
Fentanyl—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.63e-05	0.00114	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.61e-05	0.00114	CbGpPWpGaD
Fentanyl—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.59e-05	0.00113	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	2.55e-05	0.00111	CbGpPWpGaD
Fentanyl—OPRK1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.55e-05	0.00111	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—NAT2—urinary bladder cancer	2.49e-05	0.00108	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	2.49e-05	0.00108	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.48e-05	0.00108	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.47e-05	0.00108	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.47e-05	0.00108	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—RBX1—urinary bladder cancer	2.47e-05	0.00108	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.45e-05	0.00107	CbGpPWpGaD
Fentanyl—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.41e-05	0.00105	CbGpPWpGaD
Fentanyl—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.38e-05	0.00104	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TSC1—urinary bladder cancer	2.32e-05	0.00101	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.26e-05	0.000986	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—JAG1—urinary bladder cancer	2.21e-05	0.000964	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—RBX1—urinary bladder cancer	2.17e-05	0.000944	CbGpPWpGaD
Fentanyl—OPRM1—GPCR ligand binding—CXCL8—urinary bladder cancer	2.15e-05	0.000938	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—RRM2—urinary bladder cancer	2.15e-05	0.000935	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.1e-05	0.000917	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.08e-05	0.000905	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.04e-05	0.000888	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TSC1—urinary bladder cancer	2.04e-05	0.000888	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.03e-05	0.000885	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—ENO2—urinary bladder cancer	1.99e-05	0.000866	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	1.99e-05	0.000866	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—TYMP—urinary bladder cancer	1.99e-05	0.000866	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—JAG1—urinary bladder cancer	1.94e-05	0.000845	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	1.93e-05	0.00084	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.92e-05	0.000839	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.88e-05	0.000817	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.87e-05	0.000815	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.83e-05	0.000799	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—RBX1—urinary bladder cancer	1.83e-05	0.000798	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—NAT2—urinary bladder cancer	1.8e-05	0.000783	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—S100B—urinary bladder cancer	1.79e-05	0.000781	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.77e-05	0.000773	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.77e-05	0.000772	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TSC1—urinary bladder cancer	1.72e-05	0.000751	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—RHOA—urinary bladder cancer	1.7e-05	0.00074	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.69e-05	0.000736	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.64e-05	0.000716	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.64e-05	0.000715	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.64e-05	0.000715	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—JAG1—urinary bladder cancer	1.64e-05	0.000714	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—NCOR1—urinary bladder cancer	1.61e-05	0.000702	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.61e-05	0.000701	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—NQO1—urinary bladder cancer	1.6e-05	0.000698	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—S100B—urinary bladder cancer	1.57e-05	0.000685	CbGpPWpGaD
Fentanyl—OPRD1—GPCR downstream signaling—IL2—urinary bladder cancer	1.57e-05	0.000684	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—RRM2—urinary bladder cancer	1.55e-05	0.000676	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.52e-05	0.000664	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.52e-05	0.000664	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.5e-05	0.000653	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.49e-05	0.00065	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—RHOA—urinary bladder cancer	1.49e-05	0.000649	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.47e-05	0.000641	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.44e-05	0.000627	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.44e-05	0.000627	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—ENO2—urinary bladder cancer	1.44e-05	0.000626	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	1.44e-05	0.000626	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—IL2—urinary bladder cancer	1.42e-05	0.000621	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TERT—urinary bladder cancer	1.42e-05	0.000619	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—NCOR1—urinary bladder cancer	1.41e-05	0.000616	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.39e-05	0.000608	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	1.39e-05	0.000607	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—RHOA—urinary bladder cancer	1.39e-05	0.000604	CbGpPWpGaD
Fentanyl—OPRK1—GPCR downstream signaling—IL2—urinary bladder cancer	1.38e-05	0.0006	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.37e-05	0.000597	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.36e-05	0.000592	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.36e-05	0.000591	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	0.000582	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—S100B—urinary bladder cancer	1.33e-05	0.000579	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.31e-05	0.00057	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—FGFR3—urinary bladder cancer	1.3e-05	0.000568	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—ESR1—urinary bladder cancer	1.27e-05	0.000551	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—RHOA—urinary bladder cancer	1.26e-05	0.000548	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.26e-05	0.000547	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—IL2—urinary bladder cancer	1.25e-05	0.000544	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TERT—urinary bladder cancer	1.24e-05	0.000542	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—TYMS—urinary bladder cancer	1.24e-05	0.000541	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	0.000535	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	0.000535	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.22e-05	0.00053	CbGpPWpGaD
Fentanyl—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.21e-05	0.000527	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—NCOR1—urinary bladder cancer	1.19e-05	0.00052	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.19e-05	0.000517	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—GPX1—urinary bladder cancer	1.18e-05	0.000512	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.17e-05	0.00051	CbGpPWpGaD
Fentanyl—OPRM1—GPCR downstream signaling—IL2—urinary bladder cancer	1.16e-05	0.000507	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—NQO1—urinary bladder cancer	1.16e-05	0.000505	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.16e-05	0.000504	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	1.15e-05	0.000503	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—FGFR3—urinary bladder cancer	1.14e-05	0.000498	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—ESR1—urinary bladder cancer	1.11e-05	0.000484	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CREBBP—urinary bladder cancer	1.11e-05	0.000483	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—CXCL8—urinary bladder cancer	1.1e-05	0.000481	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IGF1—urinary bladder cancer	1.1e-05	0.000477	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—EGFR—urinary bladder cancer	1.09e-05	0.000475	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	0.000473	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.08e-05	0.000472	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.08e-05	0.000472	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—IL2—urinary bladder cancer	1.06e-05	0.00046	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TERT—urinary bladder cancer	1.05e-05	0.000458	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	0.000458	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—KRAS—urinary bladder cancer	1.03e-05	0.000449	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—RHOA—urinary bladder cancer	1e-05	0.000437	CbGpPWpGaD
Fentanyl—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.84e-06	0.000429	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CREBBP—urinary bladder cancer	9.72e-06	0.000424	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	9.66e-06	0.000421	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—FGFR3—urinary bladder cancer	9.65e-06	0.000421	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IGF1—urinary bladder cancer	9.6e-06	0.000418	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—EGFR—urinary bladder cancer	9.56e-06	0.000416	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—ESR1—urinary bladder cancer	9.38e-06	0.000409	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—ERBB2—urinary bladder cancer	9.29e-06	0.000405	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—TYMP—urinary bladder cancer	9.24e-06	0.000403	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—KRAS—urinary bladder cancer	9.03e-06	0.000393	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—TYMS—urinary bladder cancer	8.98e-06	0.000391	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	8.88e-06	0.000387	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	8.88e-06	0.000387	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CXCL8—urinary bladder cancer	8.81e-06	0.000384	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PPARG—urinary bladder cancer	8.8e-06	0.000383	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—RHOA—urinary bladder cancer	8.8e-06	0.000383	CbGpPWpGaD
Fentanyl—OPRD1—Signaling by GPCR—HRAS—urinary bladder cancer	8.75e-06	0.000381	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NQO1—urinary bladder cancer	8.74e-06	0.000381	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—GPX1—urinary bladder cancer	8.5e-06	0.00037	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	8.45e-06	0.000368	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—IL2—urinary bladder cancer	8.42e-06	0.000367	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.35e-06	0.000364	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	8.34e-06	0.000364	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CREBBP—urinary bladder cancer	8.22e-06	0.000358	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CCND1—urinary bladder cancer	8.21e-06	0.000358	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—ERBB2—urinary bladder cancer	8.14e-06	0.000355	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IGF1—urinary bladder cancer	8.12e-06	0.000354	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—EGFR—urinary bladder cancer	8.08e-06	0.000352	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MMP9—urinary bladder cancer	7.97e-06	0.000347	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—CDKN1A—urinary bladder cancer	7.94e-06	0.000346	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—PTEN—urinary bladder cancer	7.92e-06	0.000345	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	7.84e-06	0.000342	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CXCL8—urinary bladder cancer	7.72e-06	0.000337	CbGpPWpGaD
Fentanyl—OPRK1—Signaling by GPCR—HRAS—urinary bladder cancer	7.67e-06	0.000334	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—KRAS—urinary bladder cancer	7.63e-06	0.000332	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—EP300—urinary bladder cancer	7.55e-06	0.000329	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—RHOA—urinary bladder cancer	7.43e-06	0.000324	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—IL2—urinary bladder cancer	7.38e-06	0.000322	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—SRC—urinary bladder cancer	7.34e-06	0.00032	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTP1—urinary bladder cancer	7.29e-06	0.000318	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—RRM2—urinary bladder cancer	7.21e-06	0.000314	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CCND1—urinary bladder cancer	7.19e-06	0.000314	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MMP9—urinary bladder cancer	6.99e-06	0.000304	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—CDKN1A—urinary bladder cancer	6.96e-06	0.000303	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—PTEN—urinary bladder cancer	6.94e-06	0.000303	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	6.92e-06	0.000302	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—ERBB2—urinary bladder cancer	6.88e-06	0.0003	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—TYMS—urinary bladder cancer	6.78e-06	0.000295	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GSTM1—urinary bladder cancer	6.7e-06	0.000292	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—NCOR1—urinary bladder cancer	6.7e-06	0.000292	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.68e-06	0.000291	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.68e-06	0.000291	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—EP300—urinary bladder cancer	6.62e-06	0.000289	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—MYC—urinary bladder cancer	6.58e-06	0.000287	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CXCL8—urinary bladder cancer	6.53e-06	0.000284	CbGpPWpGaD
Fentanyl—OPRM1—Signaling by GPCR—HRAS—urinary bladder cancer	6.48e-06	0.000283	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.48e-06	0.000282	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—SRC—urinary bladder cancer	6.44e-06	0.000281	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—EGFR—urinary bladder cancer	6.44e-06	0.000281	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—GPX1—urinary bladder cancer	6.41e-06	0.000279	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PPARG—urinary bladder cancer	6.36e-06	0.000277	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—ERCC2—urinary bladder cancer	6.3e-06	0.000274	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—IL2—urinary bladder cancer	6.24e-06	0.000272	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	6.11e-06	0.000266	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—KRAS—urinary bladder cancer	6.08e-06	0.000265	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CCND1—urinary bladder cancer	6.08e-06	0.000265	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—PTEN—urinary bladder cancer	6.04e-06	0.000263	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.92e-06	0.000258	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MMP9—urinary bladder cancer	5.9e-06	0.000257	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—CDKN1A—urinary bladder cancer	5.88e-06	0.000256	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—PTEN—urinary bladder cancer	5.87e-06	0.000256	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—MYC—urinary bladder cancer	5.77e-06	0.000251	CbGpPWpGaD
Fentanyl—CYP3A7—Metabolism—EP300—urinary bladder cancer	5.76e-06	0.000251	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—EGFR—urinary bladder cancer	5.64e-06	0.000246	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—EP300—urinary bladder cancer	5.6e-06	0.000244	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—SRC—urinary bladder cancer	5.44e-06	0.000237	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—TP53—urinary bladder cancer	5.4e-06	0.000236	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.38e-06	0.000235	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—KRAS—urinary bladder cancer	5.33e-06	0.000232	CbGpPWpGaD
Fentanyl—OPRD1—Signaling Pathways—HRAS—urinary bladder cancer	5.17e-06	0.000225	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	5e-06	0.000218	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—MYC—urinary bladder cancer	4.88e-06	0.000213	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.8e-06	0.000209	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—EGFR—urinary bladder cancer	4.77e-06	0.000208	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—TP53—urinary bladder cancer	4.74e-06	0.000207	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.61e-06	0.000201	CbGpPWpGaD
Fentanyl—OPRK1—Signaling Pathways—HRAS—urinary bladder cancer	4.53e-06	0.000198	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—KRAS—urinary bladder cancer	4.51e-06	0.000196	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.49e-06	0.000196	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—PTEN—urinary bladder cancer	4.36e-06	0.00019	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.17e-06	0.000182	CbGpPWpGaD
Fentanyl—CYP3A5—Metabolism—EP300—urinary bladder cancer	4.16e-06	0.000181	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4.13e-06	0.00018	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4.13e-06	0.00018	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—TP53—urinary bladder cancer	4.01e-06	0.000175	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.95e-06	0.000172	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.88e-06	0.000169	CbGpPWpGaD
Fentanyl—OPRM1—Signaling Pathways—HRAS—urinary bladder cancer	3.83e-06	0.000167	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.78e-06	0.000165	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.65e-06	0.000159	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.29e-06	0.000143	CbGpPWpGaD
Fentanyl—ABCB1—Metabolism—EP300—urinary bladder cancer	3.14e-06	0.000137	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.96e-06	0.000129	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.84e-06	0.000124	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.33e-06	0.000101	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—PTEN—urinary bladder cancer	2.03e-06	8.84e-05	CbGpPWpGaD
Fentanyl—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.93e-06	8.43e-05	CbGpPWpGaD
